The bispecific antibody was administered as a fourth-line treatment 12 years after the patient’s diagnosis. Prior to the retrospective study presented at SOHO 2024, no study conducted a similar comparison of Dara-VTD and RVD. Prior research suggested that weekly carfilzomib at a dose of 70 mg/m2 plus dexamethasone can increase PFS. The phase III KarMMa-9 trial will review the efficacy of R maintenance alone versus with ide-cel in newly diagnosed MM. Featuring a review of third-line therapy options for CML, meeting news from the 2022 ESMO Congress, and more A debate on whether MRD negativity indicates a cure in patients with ALL, and more How chemotherapy-free regimens are more commonly being used for treatment, and more Updates on COVID-19 and hematologic malignancies, and more New goals from the Cancer Moonshot 2.0 study, and more Evidence from recent CAR T-cell therapy clinical trials, and more